共 57 条
[1]
Nussbaum RL(2003)Alzheimer’s disease and Parkinson’s disease N Engl J Med 348 1356-1364
[2]
Ellis CE(2000)Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study Brain 123 2297-2305
[3]
Schrag A(2015)Pathophysiology of Prog Neurobiol 132 96-168
[4]
Quinn N(2006)-dopa-induced motor and non-motor complications in Parkinson’s disease Lancet Neurol 5 677-687
[5]
Bastide MF(2006)Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications Nat Clin Pract Neurol 2 382-392
[6]
Meissner WG(1988)Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s disease Gen Pharmacol 19 55-60
[7]
Picconi B(2001)Therapeutic potential of selective D-1 dopamine receptor agonists and antagonists in psychiatry and neurology CNS Drug Rev 7 305-316
[8]
Olanow CW(1999)Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data Ann Neurol 45 736-741
[9]
Obeso JA(1998)ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson’s disease Clin Neuropharmacol 21 339-343
[10]
Stocchi F(2001)Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson’s disease Arch Neurol 58 249-254